bluebird bio and Regeneron Pharmaceuticals have announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against […]

Biogen and its partner Eisai have announced positive topline results from the Phase II study with anti-amyloid beta protofibril antibody BAN2401 in 856 patients with early Alzheimer’s disease. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer’s Disease Composite Score or ADCOMS, a measure of […]

Pfizer has announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These changes will be […]

Otsuka Pharmaceutical, headquartered in Tokyo, and Waltham-based Visterra have announced that Otsuka will acquire Visterra for approximately $430M in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction which is expected to close in the third quarter of 2018. Visterra’s Hierotope platform, comprised of novel computational and experimental technologies, enables […]